Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany.
Clin Infect Dis. 2023 Feb 8;76(3):e510-e513. doi: 10.1093/cid/ciac570.
Our study in 21 pediatric cancer patients demonstrates that 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA vaccine (BioNTech/Pfizer) elicited both humoral and cellular immunity in most patients during chemotherapy. Immunity was stronger in children with solid tumors and during maintenance therapy compared to those with hematological malignancies or during intensive chemotherapy. Clinical Trials Registration.ȃGerman Registry for Clinical Trials (DRKS00025254).
我们对 21 例儿科癌症患者的研究表明，在化疗期间，3 剂严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）信使 RNA 疫苗（辉瑞/BioNTech）在大多数患者中均引发了体液和细胞免疫。与血液系统恶性肿瘤或强化化疗相比，实体瘤患儿和维持治疗期间的患儿免疫力更强。临床试验注册。ȃ德国临床试验注册处（DRKS00025254）。
